AstraZeneca slides as argument continues to surround results

AstraZeneca PLC (LSE:AZN) was among the FTSE 100’s big fallers on Monday as debate raged on around the company’s year-end earnings late last week. AstraZeneca found itself still reeling from what the market deemed disappointing earnings, with brokers having punished the pharmaceuticals giant over an unchanged dividend and lack of research and development newsflow. Indeed, shares slipped a further 1.9%, adding to losses last week, after Deutsche said it would “probably keep sitting on the fence were it not f ...